John Hardy, PhD, University College London, London, UK, discusses the aducanumab clinical trial (NCT02477800, NCT024845470), which indicated that the antibody had marginal positive effects. If this is correct, it could have significant implications for Alzheimer’s disease, although it will need to be used in conjunction with other treatments. Additionally, the incidence of Alzheimer’s disease has dropped by 20% over the last 20 years. This is attributed to the increase in better cardiac health. This interview took place during the Virtual World Congress on Controversies in Neurology (CONy) 2020.
John Hardy occasionally consults for Eisai and is on the SAB of the biotech Ceracuity.